AddLife AB (publ)

OM:ALIF B Stock Report

Market Cap: SEK 16.1b

AddLife Valuation

Is ALIF B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALIF B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALIF B (SEK129.9) is trading below our estimate of fair value (SEK160.37)

Significantly Below Fair Value: ALIF B is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALIF B?

Key metric: As ALIF B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALIF B. This is calculated by dividing ALIF B's market cap by their current earnings.
What is ALIF B's PE Ratio?
PE Ratio135.3x
EarningsSEK 117.00m
Market CapSEK 16.10b

Price to Earnings Ratio vs Peers

How does ALIF B's PE Ratio compare to its peers?

The above table shows the PE ratio for ALIF B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.7x
BIOT Biotage
46.6x19.5%SEK 12.1b
MCAP MedCap
33.3xn/aSEK 7.8b
GENO Genovis AB (publ.)
65.8x16.4%SEK 1.8b
MAGLE Magle Chemoswed Holding
36.9xn/aSEK 622.0m
ALIF B AddLife
135.3x52.0%SEK 16.1b

Price-To-Earnings vs Peers: ALIF B is expensive based on its Price-To-Earnings Ratio (135.3x) compared to the peer average (45.7x).

Price to Earnings Ratio vs Industry

How does ALIF B's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ALIF B 135.3xIndustry Avg. 37.1xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALIF B is expensive based on its Price-To-Earnings Ratio (135.3x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is ALIF B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALIF B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio135.3x
Fair PE Ratio75.4x

Price-To-Earnings vs Fair Ratio: ALIF B is expensive based on its Price-To-Earnings Ratio (135.3x) compared to the estimated Fair Price-To-Earnings Ratio (75.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALIF B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 129.90
SEK 165.50
+27.4%
0.3%SEK 166.00SEK 165.00n/a2
Nov ’25SEK 136.00
SEK 165.50
+21.7%
0.3%SEK 166.00SEK 165.00n/a2
Oct ’25SEK 159.50
SEK 168.00
+5.3%
1.8%SEK 171.00SEK 165.00n/a2
Sep ’25SEK 163.00
SEK 168.00
+3.1%
1.8%SEK 171.00SEK 165.00n/a2
Aug ’25SEK 156.00
SEK 168.00
+7.7%
1.8%SEK 171.00SEK 165.00n/a2
Jul ’25SEK 125.30
SEK 142.50
+13.7%
2.5%SEK 146.00SEK 139.00n/a2
Jun ’25SEK 114.40
SEK 137.00
+19.8%
1.5%SEK 139.00SEK 135.00n/a2
May ’25SEK 102.60
SEK 137.00
+33.5%
1.5%SEK 139.00SEK 135.00n/a2
Apr ’25SEK 112.00
SEK 136.50
+21.9%
4.8%SEK 143.00SEK 130.00n/a2
Mar ’25SEK 102.40
SEK 136.50
+33.3%
4.8%SEK 143.00SEK 130.00n/a2
Feb ’25SEK 111.80
SEK 132.00
+18.1%
1.5%SEK 134.00SEK 130.00n/a2
Jan ’25SEK 109.40
SEK 111.00
+1.5%
9.9%SEK 122.00SEK 100.00n/a2
Dec ’24SEK 97.30
SEK 111.00
+14.1%
9.9%SEK 122.00SEK 100.00n/a2
Nov ’24SEK 73.35
SEK 118.00
+60.9%
15.3%SEK 136.00SEK 100.00SEK 136.002
Oct ’24SEK 64.75
SEK 135.50
+109.3%
0.4%SEK 136.00SEK 135.00SEK 159.502
Sep ’24SEK 75.50
SEK 135.50
+79.5%
0.4%SEK 136.00SEK 135.00SEK 163.002
Aug ’24SEK 85.10
SEK 135.50
+59.2%
0.4%SEK 136.00SEK 135.00SEK 156.002
Jul ’24SEK 121.70
SEK 152.50
+25.3%
1.6%SEK 155.00SEK 150.00SEK 125.302
May ’24SEK 121.20
SEK 137.50
+13.4%
1.8%SEK 140.00SEK 135.00SEK 102.602

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

AstraZeneca

UK£154.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,392.50

7D

-1.0%

1Y

4.7%

Swedish Orphan Biovitrum

SEK 102.4b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 298.20

7D

-9.1%

1Y

23.3%

Ascelia Pharma

SEK 252.2m

A biotech company, focuses on orphan oncology treatments in Sweden.

ACE

SEK 2.63

7D

-0.9%

1Y

-9.3%